Stonepine Capital Management’s Pyxis Oncology PYXS Stock Holding History

Stonepine Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.61M	Buy	+689,000	New	+$2.08M	1.01%	24

Other funds holding PYXS

Pfizer New York $164M AUM 53.62% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $373M AUM 43.9% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $33B AUM 30.04% 1-Year Est. Return

Soros Fund Management New York $8.51B AUM 25.51% 1-Year Est. Return

Stonepine Capital Management's PYXS Position: Q3 2026 in Review

Stonepine Capital Management opened a new position in Pyxis Oncology (PYXS) in Q3 2026: 689,000 shares worth $1.61M. The stake represents 1.01% of the portfolio and ranks #24 among its holdings.

65 funds tracked by Wall St. Rank hold PYXS as of Q3 2026.

Stonepine Capital Management held 689,000 shares of Pyxis Oncology worth $1.61M as of Q3 2026.
Pyxis Oncology was a new Stonepine Capital Management position in Q3 2026.
Pyxis Oncology made up 1.01% of Stonepine Capital Management's portfolio in Q3 2026, its #24 holding.
65 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2026.

Based on Stonepine Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.